Ulcerative colitis treatment continues to evolve with a growing range of targeted therapies, from S1P modulators to JAK inhibitors. Joining Dr. Peter Buch to discuss how clinicians can personalize care based on disease severity, safety profiles, and patient response is Dr. David Hudesman. He's a Professor in the Department of Medicine at NYU Grossman School of Medicine and the Director of NYU Langone’s Inflammatory Bowel Disease Center.